|1.||Guekht, Alla: 4 articles (03/2015 - 11/2012)|
|2.||Korczyn, Amos D: 3 articles (03/2015 - 11/2012)|
|3.||Grachev, S V: 3 articles (05/2014 - 01/2013)|
|4.||Astashkin, E I: 3 articles (05/2014 - 01/2013)|
|5.||Vinokurov, M G: 3 articles (05/2014 - 01/2013)|
|6.||Yurinskaya, M M: 2 articles (05/2014 - 01/2013)|
|7.||Glezer, M G: 2 articles (01/2014 - 01/2013)|
|8.||Orekhova, N S: 2 articles (01/2014 - 01/2013)|
|9.||Egorova, N D: 2 articles (01/2014 - 01/2013)|
|10.||Skoog, Ingmar: 2 articles (01/2013 - 11/2012)|
10/01/2008 - "These data lead to the conclusion that Actovegin is effective in the treatment of patients with ischemic stroke."
01/01/2013 - "A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design."
10/01/2008 - "Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke."
01/01/2013 - "The study consists of a baseline screening (≤7 days after stroke), after which eligible patients are randomised to Actovegin (2,000 mg/day for up to 20 intravenous infusions followed by 1,200 mg/day orally) or placebo for a 6-month double-blind treatment period. "
01/01/2013 - "The ongoing ARTEMIDA study will evaluate the efficacy and safety of Actovegin for the symptomatic treatment of post-stroke cognitive impairment (PSCI) and will explore whether Actovegin has any disease-modifying effect by assessing whether any changes are sustained after treatment. "
10/01/2010 - "Actovegin is effective in the prevention and treatment of chemoradiotherapy-induced oral mucositis."
10/01/2010 - "A multi-center prospective randomized trial was conducted to evaluate the efficacy and safety of Actovegin in the prevention and treatment of chemoradiotherapy-induced acute oral mucositis. "
10/01/2010 - "A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma."
08/01/2009 - "CONCLUSIONS Sequential intravenous and oral actovegin treatment over 160 days improved neuropathic symptoms, VPT, sensory function, and quality of life in type 2 diabetic patients with symptomatic polyneuropathy."
12/01/2011 - "The recently described therapeutic benefits of the hemodialysate actovegin on neuropathic symptoms in diabetic patients with symptomatic polyneuropathy suggest a neuroprotective activity of the drug. "
08/01/2009 - "Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients."
|5.||Peptic Ulcer (Peptic Ulcers)
01/01/2003 - "Combination of ILBI with actovegin proved highly effective in indolent gastroduodenal ulcers."
09/01/1993 - "[The use of actovegin in peptic ulcer]."
01/01/2003 - "To validate use of intravenous laser blood irradiation (ILBI) combined with actovegin administration in indolent gastroduodenal ulcers. "
01/01/2003 - "[Therapeutic efficiency of a combined use of low-intensity laser radiation and actovegin in gastroduodenal ulcers with inhibited cicatrix formation]."
|3.||Reactive Oxygen Species (Oxygen Radicals)
|7.||Hydrogen Peroxide (Hydroperoxide)